Acorda Therapeutics Inc. (ACOR)
0.66
-0.21 (-24.14%)
At close: Apr 03, 2024, 3:59 PM
-24.14% (1D)
| Bid | n/a |
| Market Cap | 821.03K |
| Revenue (ttm) | 115.66M |
| Net Income (ttm) | -263.43M |
| EPS (ttm) | -203.57 |
| PE Ratio (ttm) | -0.00324704033010758 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 321,668 |
| Avg. Volume (20D) | 125,680 |
| Open | 0.78 |
| Previous Close | 0.87 |
| Day's Range | 0.61 - 0.85 |
| 52-Week Range | 0.61 - 24.20 |
| Beta | 1.46 |
About ACOR
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS p...
Sector Healthcare
IPO Date Feb 10, 2006
Employees 102
Stock Exchange NASDAQ
Ticker Symbol ACOR
Website https://www.acorda.com